Sign in
Taking people in United StatesPhase 2

Scans to find the hidden tumor causing ectopic Cushing syndrome

Tests two PET scans for locating the source of excess ACTH hormone.

Key facts

Who runs it
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Where
Bethesda, United StatesSee the site
Trial code
Registry title
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
Status
Recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
12 Feb 2014
Expected to end
31 Dec 2030
Type of study
Interventional
Treatments tested
  • DOTATATE PET-CT
  • F-DOPA PET CT
  • CT scan
  • Routine MRI scan
  • Gated MRI scan
  • 68Ga-DOTATATE
  • 18F-DOPA
Record updated
2 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have, or may have, ectopic Cushing syndrome. This means a tumour outside the pituitary gland makes the hormone ACTH. The trial tests PET scans to find this tumour.

Age
18 to 90 years in the criteria text; the record's age fields say 18 to 80 years.
Sex
All sexes can join.
Disease stage
A history of ectopic Cushing syndrome, or a diagnosis saying it may be ectopic Cushing syndrome.
Earlier treatment
People who have already had ten or more F-DOPA PET/CT scans and ten or more DOTATATE scans cannot join.

Main reasons for not taking part

  • Being pregnant or breastfeeding.
  • A severe active infection.
  • Serious heart problems, or blood clotting, blood count, liver or kidney test results outside the limits the record sets.
  • Body weight over 136 kg (300 lb).
  • More than 450 ml of blood taken in total in the six weeks before the study.

The registry criteria, word for word

Show all 14 criteriaShow less

Who cannot take part

  • Pregnancy or lactation; the radiation associated with PET and CT scans may be harmful to a developing fetus. Likewise the ingestion of radionuclides in breast milk has an unknown risk to an infant
  • Subjects who previously underwent ten or more F-DOPA PET/CT scans and ten or more DOTATATE scans
  • Evidence of severe active infection
  • Clinically significantly impaired cardiovascular function, abnormal coagulation in the absence of medically-indicated treatment (PT and PTT elevated by 30% above the normal values), hematopoietic (hematocrit less than 30%, hemoglobin below 10 g/dl, white count below 3000 K/UL, and platelets below 100,000 K/mm\^3), hepatic (liver enzymes elevated by 4-fold above normal values), or renal function (plasma creatinine level over 2.1)
  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Based on the clinical judgment of the attending physician, other medical problems may prompt exclusion
  • Body weight over 136 kg, which is the limit for the tables used in the scanning areas
  • Combined blood withdrawal during the six weeks preceding the study greater than 450 ml

Other criteria

  • INCLUSION CRITERIA:; To be eligible to participate in this study, an individual must meet all of the following criteria:
  • 18 - 90 years of age
  • Medical history of ectopic Cushing syndrome or diagnosed with the possibility of ectopic Cushing syndrome
  • For females of reproductive potential: agreement to use highly effective contraception for at least 2 weeks before any PET scan
  • Ability of subject to understand and the willingness to sign a written informed consent document
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Raven N McGlotten, R.N.Taking people

About the trial

What the trial wants to find out

Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess. In approximately 50% of these patients, the tumoral source of ACTH cannot be found initially despite very detailed and extensive imaging, including studies such as computed tomography, magnetic resonance imaging, and octreotide scan (Octreoscan) using the standard dose of indium- 111 pentetreotide ([111In-DTPA-D-Phe]-pentetreotide). The sensitivity and specificity of structurally based imaging studies depends on anatomic alterations and the size of the tumor. In contrast, positron emission tomography (PET) and somatostatin ligand imaging detect pathologic tissue based on physiologic and biochemical processes within the abnormal tissue. This protocol tests the ability of [18F]-L-3,4-dihydroxyphenylalanine (18F-DOPA) PET, and the somatostatin imaging analogue, 68Ga-DOTATATE-PET, to localize the source of ectopic ACTH production.

The group in the trial

  • ImagingTreatment being tested

    All subjects will be imaged

    Treatment: DOTATATE PET-CT, F-DOPA PET CT, CT scan, Routine MRI scan, Gated MRI scan, 68Ga-DOTATATE, and 18F-DOPA

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
Plain-language title
Scans to find the hidden tumor causing ectopic Cushing syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT02019706, who can take part
Record updated
2 October 2026